Assessing the inactivation capabilities of two commercially available platelet component pathogen inactivation systems: effectiveness at end of shelf life
- 22 February 2021
- journal article
- research article
- Published by Wiley in Vox Sanguinis
- Vol. 116 (4) , 416-424
Abstract
Background and objectives: The inactivation capabilities of the two current commercially available pathogen inactivation (PI) systems for platelet components (PC), Mirasol and Intercept, were investigated by determination of the absence of viable bacteria at the end of shelf life by testing the entire contents of the PC by enrichment culture (terminal sterility).Methods: A pool‐and‐split method was used, with two treated units and one untreated control per inoculum concentration. Pairs of PC bags were inoculated with a single bacterial species. Three concentrations (n = 2 per concentration), which incremented tenfold, were tested initially based on published data from the manufacturer. Dependent on these results, the concentrations subsequently tested were either increased or decreased until the inactivation capability of the system was derived. Bacterial count was determined post‐spiking, immediately prior to treatment (2 h from spiking), immediately after treatment and at the end of shelf life (day seven). Enrichment culture was performed immediately prior to treatment, after treatment and at the end of shelf life.Results: The inactivation capabilities, in CFU/ml, of Intercept and Mirasol, respectively, at the end of PC shelf life were as follows: Staphylococcus aureus ≥ 107, 1; Staphylococcus epidermidis ≥106, 2; Klebsiella pneumoniae 105, 1; Streptococcus bovis ≥107, 101, Escherichia coli ≥106, 1; Streptococcus pneumoniae ≥106, 103; Streptococcus mitis ≥107, 101; Listeria monocytogenes ≥107, 101; Streptococcus dysgalactiae ≥107, 1; Serratia marcescens 103, 1; Pseudomonas aeruginosa 103, Mirasol not tested; and Bacillus cereus < 102, Mirasol not tested.Conclusion: The inactivation capability of Intercept was greater than that of Mirasol. Inactivation capability (by terminal sterility) is the most meaningful measure to evaluate a PI system for bacteria, rather than logarithmic reduction assessed immediately after treatment by plate count. PI offers a possible alternative to bacterial screening if treatment is performed at an appropriate time dependent on the inactivation capabilities of the system.Keywords
This publication has 18 references indexed in Scilit:
- Evaluation of the effectiveness of a pathogen inactivation technology against clinically relevant transfusion‐transmitted bacterial strainsTransfusion, 2015
- Pathogen inactivation efficacy of Mirasol PRT System and Intercept Blood System for non‐leucoreduced platelet‐rich plasma‐derived platelets suspended in plasmaVox Sanguinis, 2014
- Bacterial culture of apheresis platelets: a mathematical model of the residual rate of contamination based on unconfirmed positive resultsVox Sanguinis, 2013
- Clostridium perfringens in apheresis platelets: an unusual contaminant underscores the importance of clinical vigilance for septic transfusion reactions (CME)Transfusion, 2013
- UVC Irradiation for Pathogen Reduction of Platelet Concentrates and PlasmaTransfusion Medicine and Hemotherapy, 2011
- A novel rapid and effective donor arm disinfection methodTransfusion, 2009
- A laboratory comparison of pathogen reduction technology treatment and culture of platelet products for addressing bacterial contamination concernsTransfusion, 2009
- Photochemical treatment of platelet concentrates with amotosalen and long‐wavelength ultraviolet light inactivates a broad spectrum of pathogenic bacteriaTransfusion, 2004
- ORIGINAL PAPER. Relative values of the interventions of diversion and improved donor‐arm disinfection to reduce the bacterial risk from blood transfusionVox Sanguinis, 2004
- Salmonella Sepsis Caused by a Platelet Transfusion from a Donor with a Pet SnakeNew England Journal of Medicine, 2002